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Abstract In a new prescribing qualification course for spe-
cialist oncology nurses, we thought that it is important to
emphasize pharmacovigilance and adverse drug reaction
(ADR) reporting. We aimed to develop and evaluate an
ADR reporting assignment for specialist oncology nurses.
The quality of report documentation was assessed with the
BClinical Documentation tool to assess Individual Case
Safety Reports^ (ClinDoc). The relevance of the reports was
evaluated in terms of ADR seriousness, the listing for addi-
tional monitoring of the drug by European Medicines Agency
(EMA), and lack of labelling information about the ADR.
Nurses’ opinions of the assignment were evaluated using an
E-survey. Thirty-three ADRs were reported, 32 (97%) of
which were well documented according to ClinDoc.
Thirteen ADRs (39%) were Bserious^ according to CIOMS
criteria. In five cases (15%), the suspect drugs were listed for
additional monitoring by EMA and in seven cases (21%), the
ADR was not mentioned in the Summary of Product
Characteristics. Twenty-five (78.1%) of the 32 enrolled nurses
completed the E-survey. Most were > 45 years of age (68%),
female (92%) and had extensive clinical experience (6–
33 years). All agreed or completely agreed that the reporting
assignment was useful, that it fitted in daily practice and that it
increased their attention for medication/patient safety. A large
majority (84.0%) agreed the assignment changed how they
dealt with ADRs. Specialist oncology nurses are capable of
reporting ADRs, and they considered the assignment useful.
The assignment yielded valuable, relevant, and well-
documented ADR reports for pharmacovigilance practice.
Keywords Oncology nurses . Nursing education .
Pharmacotherapy . Pharmacovigilance . ADR reporting
Introduction
The spontaneous reporting of adverse drug reactions (ADRs)
by health professionals is a widely used method for ADR
detection (Miguel et al. 2013). This is vital for identifying
unknown, uncommon and serious ADRs, with a view to im-
proving medication safety and understanding the risks of
drugs (Molokhia et al. 2009; Sultana et al. 2013). However,
this spontaneous reporting system is dependent on the respon-
siveness of health professionals and on the quality and quan-
tity of their ADR reports. Reporting ADRs is typically the
responsibility of physicians and is mandatory in some coun-
tries such as the Netherlands (Hazell and Shakir 2006; Lopez-
Gonzalez et al. 2009; Molokhia et al. 2009). Nevertheless,
underreporting remains a barrier to optimal ADR monitoring
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(Hazell and Shakir 2006; Lopez-Gonzalez et al. 2009;
Molokhia et al. 2009). To stimulate ADR reporting, pharma-
cists, medical/pharmacy students, patients, and nurses are now
authorized to report ADRs, which has the added advantage of
obtaining information from other, non-physician sources (van
Grootheest et al. 2003; Steurbaut and Hanssens 2014; van
Eekeren et al. 2014; Harmark et al. 2015).
Nurses are a potentially valuable source of ADR reports,
because they administer most drugs in hospitals and are often
present when an ADR occurs (Hall et al. 1995). Furthermore,
nurses report different types of suspected ADRs from those
reported by physicians; for instance, they report more side
effects after parenteral administration (Hall et al. 1995;
Sacilotto et al. 1995; Ranganathan et al. 2003; Bigi and
Bocci 2017). Although nurse reporting seems promising, it
has been queried whether nurses are adequately prepared for
this role. Previous studies have shown that they have little
knowledge and poor practice regarding pharmacovigilance
and the spontaneous reporting system (Hanafi et al. 2012;
Hanrath 2016; Salk and Ehrenpreis 2016). Moreover, a recent
literature review emphasized the need for pharmacovigilance
training in (postgraduate) nurse education (Bigi and Bocci
2017).
When we developed a new prescribing qualification
course for specialist oncology nurses, we wanted to focus
attention on their role in drug safety. Although this prescrib-
ing qualification allows nurses to prescribe a limited set of
drugs, their role in pharmacovigilance would cover the entire
field of oncology, with its multiple drugs, many of which give
rise to serious ADRs. It is unclear how to best prepare
(specialist) nurses for this task. Some interventions have been
shown to be effective for qualified physicians, but few studies
have investigated other health professionals receiving further
training (Pagotto et al. 2013). While passive educational
methods (e.g. lectures) are typically used during training
(Rosebraugh et al. 2003; Durrieu et al. 2007), those being
taught prefer active learning forms (Elkalmi et al. 2011;
Gavaza and Bui 2012; Schutte et al. 2017c). Such active
learning approaches are preferential for adult learners
(Yardley et al. 2012). By combining the preference for an
active learning approach and our experience with a student
ADR-reporting assignment (van Eekeren et al. 2014; van
Eekeren and Schutte 2015), we hypothesized that an ADR
reporting assignment would be a suitable approach for train-
ing the pharmacovigilance skills of specialist oncology
nurses.
Therefore, the primary objective of this study was to estab-
lish the value of an ADR reporting assignment to
pharmacovigilance centres and specialist nurses following a
prescribing training course. A secondary objective was to
evaluate the preparedness of these specialist nurses for their
role in pharmacovigilance, their intention/attitudes and skills/
towards pharmacovigilance and ADR reporting.
Methods
Setting
The Amstel Academy (VU University Medical Center) offers
registered specialist oncology nurses a course on prescribing
to enable them to qualify to prescribe a limited set of frequent-
ly prescribed drugs (anti-diarrhoea drugs, anti-emetics, anal-
gesics (non-opioids) and benzodiazepines). Nurses follow the
course in addition to their work in different (most non-
academic) hospitals in the Netherlands. The course consists
of 4 days (6 h/day) spread over half a year, completed by a
prescribing assessment. The module overview is displayed in
Fig. 1. It covers pharmacovigilance by means of a lecture on
pharmacovigilance and a practical ADR reporting assignment.
The reporting assignment was introduced during a
pharmacovigilance lecture, in which the nurses were
instructed to report an ADR that was either unknown, excep-
tional or unexpected to them. The assignment was followed
by a group discussion of the ADRs reported, led by a pharma-
cotherapy teacher (T.S . ) and assessor f rom the
Pharmacovigilance Centre Lareb (R.vE.).
Population
Thirty-two specialist oncology nurses enrolled for this course
in November 2015 in two separate groups. All were invited to
voluntarily participate in this study and complete an anony-
mous E-questionnaire after the course. Based on previous E-
questionnaire studies, we expected a response rate of 25–50%.
Instruments
Two aspects of the course were evaluated. First, the quality of
documentation and relevance of the ADRs reported and sec-
ond, the nurses’ perspective of the reporting assignment to-
gether with their current attitudes and skills regarding
pharmacovigilance and ADR reporting.
The quality of documentation of the reported ADRs was
measured by an assessor from the Pharmacovigilance Centre
Lareb, using the novel BClinical Documentation tool to assess
Individual Case Safety Reports^ (ClinDoc). The ClinDoc tool
was previously described by Rolfes and provides a complete-
ness score (0–100%) (Rolfes et al. 2016a; Oosterhuis et al.
2016; Rolfes et al. 2016b; Rolfes et al. 2017). It assesses the
relevance of the information provided in an ADR report (e.g.
information on the ADR, time relationship, drug, and patient
characteristics). The ClinDoc is displayed in Table 1.
The relevance of the reported ADR was assessed with re-
spect to label information for the suspect drug (in Summary of
Product Characteristics), seriousness of the ADR (According
to CIOMS criteria 1999), additional monitoring of the drug,
off-label use of the drug and severity of the ADR as a reason to
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stop necessary treatment. The nurses were not informed that
their reports would be assessed for completeness.
The nurses’ perspective was evaluated with an E-
questionnaire covering three themes (intention/attitudes,
knowledge/skills and evaluation of pharmacovigilance
teaching) in 13 questions. Participants were sent an informa-
tion letter and returned an informed consent statement before
they completed the questionnaire. They also provided infor-
mation about baseline characteristics, including their earlier
ADR reporting experience and whether ADR reporting was
Table 1 The ClinDoc tool
(clinical documentation score), as
it is developed by Lareb as part of
WEB-RADR (WEB-
RADR 2017; Rolfes et al. 2017).
The ClinDoc tool comprises four
domains: (1) description of the
ADR, (2) description of the chro-
nology of the ADR, (3) suspected
drug and (4) patient characteris-
tics. These domains consist of
multiple subdomains. Firstly, an
Individual Case Safety Reports
(ICSRs) can be scored using this
tool by first identifying which
subdomains are relevant.
Secondly, the assessor indicates if
this relevant information was
present or absent. Domain scores
are calculated by dividing the
score for present information by
the number of subdomains
deemed relevant. The final score
is the mean of the domain scores.
This final score can be
categorised into three categories
of reporting completeness, being
well (≥ 75%), moderately (45–
75%) or poorly (≤ 45%)
The ClinDoc tool
Relevant?
Yes (+ 1) No (n.a.)
Present?
Yes (+ 1) No (0)
Domain
score
1: Description of the adverse drug reaction (ADR)
a Proper description of the ADR
b Specification complaints Blocalization^ and
Bcharacterization^
To strengthen the diagnosis (item c or d or e if
applicable):
c Treatment; or
d Visual material (photo, video); or
e Lab values, test
2: Description of the chronology
a Latency
b Description of the course of the ADR
c Action taken on drug
d Outcome of the ADR
3: Suspected drug
a Brand name in case of drug substitution?
b Different forms or route of administration for
suspected drug?
c Dose-relationship with ADR?






d Patient’s lifestyle or other risk factors
Fig. 1 Overview of the first course on prescribing at the Amstel
Academy (VU University Medical Center) for specialist oncology
nurses between November 2015 and May 2016. The nurses follow the
course in addition to their work in different (most non-academic)
hospitals in the Netherlands which is depicted in the white boxes. The
course consists of 4 days (6 h/day) equally spread over half a year, which
is depicted as black boxes. Within these boxes, the discussed themes are
noted. The nurses were instructed regarding the reporting assignment
during a lecture in day 2 (January). This lecture included a general
lecture on pharmacovigilance in the Netherlands. The ADRs had to be
reported before the group discussion (day 4, inMarch). Following the last
day of the module, the evaluation survey was distributed
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covered in their initial training as nurse. In the E-question-
naire, once a question was answered, it was not possible for
respondents to return to earlier answers (since some questions
consisted of the answers to earlier questions). There was no
time limit for E-questionnaire completion, but on the basis of a
pilot study, we estimated that it would take 8–10 min to com-
plete. The first two themes intention/attitudes and knowledge/
skills regarding pharmacovigilance and ADR reporting were
investigated using a set of open-ended question and dichoto-
mous questions that were used in earlier studies (Schutte et al.
2017c; Schutte et al. 2017d). The third theme was an evalua-
tion of the ADR-reporting assignment and (previous)
pharmacovigilance teaching. This theme consisted of the open
question Bwhat have you learned?^ and 18 statements that
covered participants’ opinions of the ADR-reporting assign-
ment, discussion of the ADR-reporting assignment, their cur-
rent and past education in pharmacovigilance and whether
they considered this education sufficient and appropriate for
future clinical practice. Answers were scored on a Likert scale
(5- or 7-point). The complete questionnaire is displayed in
Appendix 1.
Data analysis
All data were imported in SPSS Statistics 22 (IBM Corp.;
Armonk, NewYork). Descriptive statistics were used to report
frequencies and means/standard deviations (SD) of survey
results. Open questions were analysed using content/
thematic analysis (Braun and Clarke 2006). The mean com-
posite knowledge score was calculated as the sum of the cor-
rect answers divided by the number of questions answered
(uncorrected for guessing). Skills were analysed as two sepa-
rate outcomes (i.e. knowing where to report and knowing
what to report). A significance level with an alpha of 5%
was considered statistically significant (p < 0.05) in all
analyses.
Results
All 32 oncology nurses enrolled in the prescribing qualifica-
tion course were invited to participate in this study by e-mail;
25 completed the questionnaire, yielding a response rate of
78.1%. Of the responders, 23 were female (92%), 22 (68%)
were 45 years or older and their clinical experience as nurse
ranged between 6 and 33 years. While 19 nurses (76%) re-
ported that their initial training curriculum covered ADRs,
only 2 nurses (8%) indicated that the curricula covered the
reporting of ADRs. Before they enrolled, 7 nurses (28%)
had reported one or more ADRs to the Pharmacovigilance
Centre Lareb.
Quality and relevance of reports
A total of 33 Individual Case Safety Reports (ICSRs) were
reported during the assignment, accounting for 41 ADRs. In
23 (70%) of the ICSRs, the suspect drug was a cytostatic
agent, used in the treatment of malignant diseases.
Gastrointestinal disorders and skin reactions were the most
frequently reported ADRs. Overall, 32 (97%) of the reports
were well documented. Most ICSRs were considered relevant,
in terms of seriousness (according to CIOMS) of the ADR
(n = 13, 39%), lack of label information about the reported
ADR (n = 7, 21%), additional monitoring of the suspect drug
by EMA (European Medicine Agency; n = 4, 12%), the ADR
being the cause of withdrawal of a cytostatic drug (n = 4, 12%)
and off-label use of the suspect drug (n = 2, 6%). Eleven
(33%) reports used hospitalization as criterion of ADR seri-
ousness, one used a life-threatening situation and one used
death. Further details regarding ICSRs, ClinDoc score and
relevance are displayed in Table 2 and Appendix 1.
The ADR-reporting assignment and pharmacovigilance
teaching
The 25 participants agreed that the reporting assignment was
useful, that it was consistent with their daily work and duties
and that it made them more aware of medication and patient
safety. Only nine participants (36.0%) thought that the
reporting assignment cost a lot of time. Twenty-one partici-
pants (84.0%) agreed that the reporting assignment changed
how they dealt with ADRs. The results of the participant eval-
uation are displayed in Fig. 2.
Intention/attitudes
After participation, all the nurses reported they intended to
report serious and unknown ADRs, because reporting them
Bcontributed to medication safety^ and Bimproved patient
safety .^ They also considered that it was Bpersonally
beneficial^ and Beducated others about drug risks^. The
nurses did not consider that reporting ADRs would Bbreak
trust with patients^ or that it would Bincrease the risk of
malpractice^. The nurses’ attitudes towards ADR reporting
in different situations are displayed in Table 3.
Knowledge and skills
After the reporting assignment, all 25 nurses who returned
the questionnaire said they knew where to report ADRs, and
all but one (96%) knew what information was needed to fill
in an ADR report. The mean score for the 12 knowledge
questions was 75% (SD 13). The results for the individual
questions are displayed in Table 4. Analysis of the open-
ended questions showed that nurses considered that they
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had learned why it is important to be aware of ADRs and
how to recognize them, that they had experienced and
learned how and what to report and that they had learned
more about the Pharmacovigilance Centre Lareb and its role
in assessing ADRs, in providing feedback, and as knowl-
edge centre for drug safety (Table 4).
Table 2 Information about
characteristics, clinical
documentation score and
relevance of Individual Case
Safety Reports, reported by
specialist oncology nurses and
assessed by the
pharmacovigilance assessors
using the Clinical documentation
(ClinDoc) tool (see Table 1)
Individual Case Safety Reports
Number of Individual Case Safety Reports n = 33
Number of reported ADRs (grouped by System Organ Class) n = 41
Clinical documentation score (overall) (%)
Mean (range) 89% (61–100%)
Median 92%
Clinical documentation score, domain 1
Mean (range) 84% (50–100%)
Median 100%
Clinical documentation score, domain 2
Mean (range) 88% (67–100%)
Median 100%
Clinical documentation score, domain 3
Mean (range) 100% (100–100%)
Median 100%
Clinical documentation score, domain 4
Mean (range) 93% (33–100%)
Median 100%
Type of drug
Cytostatic n = 23 (70%)
Supporting n = 7 (21%)
Diagnostic n = 1 (3%)
Other treatment n = 2 (6%)
System Organ Class of reported ADRs (%)
Gastrointestinal disorders n = 10 (30%)
Skin and subcutaneous tissue disorders n = 10 (30%)
Respiratory, thoracic and mediastinal disorders n = 4 (12%)
Eye disorders n = 3 (9%)
Nervous system disorders n = 3 (9%)
Psychiatric disorders n = 2 (6%)
Blood and lymphatic system disorders n = 1 (3%)
Cardiac disorders n = 1 (3%)
Drug interaction n = 1 (3%)
General disorders and administration site conditions n = 1 (3%)
Hepatobiliary disorders n = 1 (3%)
Immune system disorders n = 1 (3%)
Musculoskeletal disorders n = 1 (3%)
Renal and urinary disorders n = 1 (3%)
Reproductive and breast disorders n = 1 (3%)
Relevance of reported ICSR (%)
Seriousness n = 13 (39%)
ADR not labelled n = 7 (21%)
Additional monitoring of drug n = 5 (15%)
ADR cause of withdrawal of oncolytic therapy n = 4 (12%)
Off-label use of drug n = 2 (6%)
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Discussion
Specialist oncology nurses are capable of reporting ADRs, as
evidenced by their good clinical documentation of the ICSRs
and by the relevance of their reports. The reporting assignment
yielded valuable, relevant and well-documented ADR reports
for pharmacovigilance. The nurses were ready for their role in
pharmacovigilance practice, had positive attitudes/intentions
and had adequate skills/knowledge about pharmacovigilance
and ADR reporting after they had completed the prescribing
qualification course.
The value of ADR reports made by health professionals
receiving further training has not been studied earlier with a
validated instrument. An earlier study of nurses reported that
only 48% (95% CI 42.4–53.7) of ADR forms were complete
in all relevant aspects (Ranganathan et al. 2003). Furthermore,
healthcare professionals scored a mean of 78% on the
ClinDoc instruments’ pilot study (Rolfes et al. 2016b). The
levels of completeness of both referenced studies are consid-
erably lower compared to the mean 89% ClinDoc score in the
present study. The high scores for clinical documentation of
the ICSRs in the present study show that specialist oncology
nurses are highly capable of providing relevant and appropri-
ate information in their ADR reports, even in a training
situation.
Most of the reported ADRs were very relevant for
pharmacovigilance, most frequently because the ADR was
serious or the suspect drug was listed by EMA for additional
monitoring. In 39% of the ICSRs, the ADR was serious ac-
cording to CIOMS criteria, a significantly higher percentage
than reported in three earlier studies of ADR reporting by
nurses. In a study by Ranganatan, nurses reported a higher
proportion of serious suspected ADRs than general practi-
tioners and hospital physicians (13.5 versus 12.9 and 9.1%,
respectively) (Ranganathan et al. 2003). The opposite was
found in a French study in 1995, which found that doctors
reported more (suspected) serious ADRs than nurses (19 ver-
sus 10%, respectively) (Sacilotto et al. 1995). In a previous
study in the Netherlands, 25% of ADRs reported by health
professional were considered serious (Rolfes et al. 2015). The
higher number of serious ADRs in our present study is prob-
ably due to the high frequency of severe and serious ADRs to
the cytostatic agents used in oncology. Although specialist
oncology nurses are only permitted to prescribe a small set
of supportive drugs, they apparently felt responsible for
reporting ADRs to the cytostatic agents themselves.
The specialist oncology nurses had positive attitudes/
in tent ions and adequate ski l l s /knowledge about
pharmacovigilance and ADR reporting. Almost all nurses
intended to report serious ADRs in the future (mean 6.6 SD
0.6). The specialist oncology nurses had higher scores in this
respect than medical students (mean 6.2; SD 1.0) (Schutte
et al. 2017c), pharmacists (mean 5.2; SD 1.5) (Gavaza et al.
2011) and pharmacy students (mean 5.9; SD 1.5) (Gavaza and
Bui 2012), who were all assessed with the same questionnaire.
These results are possibly related to the nurses’ expectations
regarding the relevance, benefits and costs of reporting.
Although the nurses expected reporting to be somewhat time
consuming (mean 4.5 SD 1.6 on 7-point Likert scale), phar-
macists thought that it would be more time consuming (mean
5.1 SD 1.6) (Gavaza et al. 2011). More nurses than pharma-
cists considered that reporting is Bpersonally beneficial^
(mean 6.2 SD 0.6 versus mean 5.0 SD 1.6, respectively)
(Gavaza et al. 2011). Furthermore, their skills and knowledge
in pharmacovigilance were considerably better than those of
final-year medical students in the Netherlands (scores of 75
versus 68% for basic pharmacovigilance knowledge, respec-
tively) (Schutte et al. 2017c). All but one of the nurses knew
where and what was necessary to report for a good ADR
report. This was far better than final-year medical students,
of whom 78% knew where they should report an ADR and
33% knew what was necessary for a good ADR report. The
ADR-reporting assignment and plenary discussion were con-
sidered useful by the nurses, and they commented that it
changed how they dealt with ADRs. All these findings are
important as they potentially influence the willingness and
likelihood of these nurses reporting serious ADRs in the
future.
The main limitation of this study is its relative small sample
size and design—there was no pre-participation measurement
or control group. Moreover, the population mainly consisted
of experienced female nurses. Furthermore, the educational
setting might have biased results, since the nurses may have
put more effort into the assignment than they would do in their
Fig. 2 Results of evaluation (on a 5-point Likert scale) of a
pharmacovigilance reporting assignment, part of a prescribing qualifica-
tion course for specialist oncology nurses, and discussion of reported
adverse drug reactions (ADRs)
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Table 4 Knowledge/skills regarding the reporting of adverse drug reactions and open feedback on what the specialist oncology nurses perceived they
had learned (some quotes/examples fit into more than one theme)
Skills and knowledge of reporting adverse drug reactions (ADRs) and pharmacovigilance
Total
Students who did not know where to report an ADR 0
Students who did not know which items were necessary for a good
ADR report
1 (4%)
% with correct answer
1. All ADRs, irrespective of severity, must be reported (*no) 36
2. Doctors should report serious ADRs even if uncertain that product
caused the event (*yes)
100
3. Doctors should report serious ADRs even if do not have all details
of event (*yes)
92
4. All serious ADRs are known before a drug is marketed (*no) 84
5. Lareb does not disclose ADR reporter’s identity (*yes) 84
6. One can report ADRs anonymously to Lareb (*yes) 76
7. Adverse experiences with cosmetics and special nutritional
products may be reported to Lareb (*yes)
28
8. Adverse experiences with natural or homeopathic products may
be reported to Lareb (*yes)
60
9. Adverse experiences with vaccines may be reported to Lareb
(*yes)
100
10. One case reported by a doctor does not contribute much to
knowledge about drug risks (*no)
72
11. I have adequate knowledge of ADR reporting (*yes) 92
12. Patients can report ADRs independent from a healthcare
professional (*yes)
80
Total 12 knowledge questions 75 (SD 13)
Qualitative results—student reflections of what they learned
Themes Examples
Adverse drug reactions
Awareness Being more aware of adverse drug reactions, no longer the attitude Bthat’s
part of the job^.
Now, I have a different perspective on all drugs patients use, I am aware of
possible interactions and side effects of drugs.
Recognizing Figuring out which drug could have caused the adverse drug reaction was
very useful, and also to search for alternative causes underlying the
adverse drug reaction.
Recognizing adverse drug reactions.
It was very instructive to search for the drug that could have caused a
certain adverse drug reaction.
Reporting
How to report/experience Where and how to report an adverse drug reaction. Because you make
a report yourself, you learn at the same time. The assignment was
good and fits well together with my daily work and duties.
Being well prepared to report the adverse drug reaction, there are many
queries in the report form. I first read the entire report form to prepare myself.
What information to collect and report Which items are necessary for an ADR-report.
Figuring out properly and accurately what the complaints are. Making
sure I collect all information necessary.
Why to report/importance The course made me aware why it is important to report. It felt good
to do so and contribute to better information regarding available information.
I think it is important everyone reports, because by doing so, some
drugs would not be prescribed so easily and furthermore we could
better inform patients regarding highly prevalent side-effects.
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usual workplace settings. Taken these limitations into account,
this study showed the value of an ADR reporting assignment,
as it offered oncology nurses valuable experience and training
while providing valuable and relevant ADR reports for
pharmacovigilance. Earlier studies have demonstrated compa-
rable positive outcomes of giving learners legitimate roles in
real (pharmacotherapy) problems of real patients (Dekker
et al. 2015; Schutte et al. 2017a; Schutte et al. 2017b).
Given the positive results of the ADR reporting assignment
in this population, future research should focus on optimiza-
tion of pharmacovigilance education for health professionals,
especially assignments that are grounded in real practice. Such
research should study the long-term effects of educational
interventions and whether less experienced health profes-
sionals are also capable of contributing to pharmacovigilance
while performing practical assignments in real practice, as we
demonstrated in this study. To conclude, the adverse drug
reaction reporting assignment yielded valuable, relevant and
well-documented ADR reports for pharmacovigilance. In ad-
dition, this assignment was considered educational by the spe-
cialist oncology nurses. The participating nurses had positive
attitudes/intentions and had adequate skills/knowledge about
pharmacovigilance and ADR reporting after they had com-
pleted the prescribing qualification course.
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